Voya Investment Management LLC cut its stake in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 53.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,427 shares of the company's stock after selling 24,533 shares during the quarter. Voya Investment Management LLC's holdings in Apogee Therapeutics were worth $801,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock valued at $921,000 after purchasing an additional 694 shares in the last quarter. Brooklyn Investment Group purchased a new stake in Apogee Therapeutics during the first quarter valued at $42,000. AlphaQuest LLC bought a new position in Apogee Therapeutics during the first quarter valued at $43,000. Rhumbline Advisers increased its position in Apogee Therapeutics by 3.2% during the first quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock valued at $2,032,000 after acquiring an additional 1,665 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Apogee Therapeutics by 1.8% in the fourth quarter. Nuveen Asset Management LLC now owns 137,826 shares of the company's stock worth $6,244,000 after purchasing an additional 2,480 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Apogee Therapeutics
In related news, insider Carl Dambkowski sold 10,090 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total transaction of $454,958.10. Following the sale, the insider directly owned 238,998 shares in the company, valued at approximately $10,776,419.82. This trade represents a 4.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 15,540 shares of company stock valued at $661,104. Insiders own 42.77% of the company's stock.
Analyst Ratings Changes
Several analysts have commented on the stock. Wedbush reissued an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, August 11th. Guggenheim reaffirmed a "buy" rating and set a $116.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. BTIG Research lifted their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Finally, Zacks Research cut shares of Apogee Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $97.29.
View Our Latest Analysis on APGE
Apogee Therapeutics Price Performance
Apogee Therapeutics stock opened at $38.42 on Thursday. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The business has a 50 day simple moving average of $37.70 and a 200-day simple moving average of $38.19. The stock has a market capitalization of $1.77 billion, a PE ratio of -9.30 and a beta of 1.42.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). As a group, equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.
About Apogee Therapeutics
(
Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
See Also
Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
